3.4.22.B50	C270A/H332A	active site mutant	732827	
3.4.22.B50	C1732A	encodes a substitution of a cysteine residue, predicted to be critical for zinc binding	-, 670084	
3.4.22.B50	C106A	inactive	718275	
3.4.22.B50	T312A/I313V/I353R	mutant lacks deubiquitinase activity, amino acid numbering based on polyprotein	-, 755638	
3.4.22.B50	T39W	mutation enhances hydrolysis of the SARS-CoV-derived peptidyl substrate Dabcyl-FRLKGGAPIKGV-Edans	752517	
3.4.22.B50	C1651A	Plpro active-site mutant	-, 670085	
3.4.22.B50	C1651A	purified SARS-CoV PLpro protein containing an alanine substitution at putative catalytic residues	-, 670084	
3.4.22.B50	D1826A	purified SARS-CoV PLpro protein containing an alanine substitution at putative catalytic residues	-, 670084	
3.4.22.B50	C112S	site-directed mutagenesis, active site cysteine mutant, forms a noncovalent complex with ubiquitin, crystal structure analysis	731149	
3.4.22.B50	Y274A	site-directed mutagenesis, inactive mutant	731069